HBK Sorce Advisory LLC Acquires 42,951 Shares of Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC lifted its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 33.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 170,577 shares of the biotechnology company’s stock after buying an additional 42,951 shares during the period. HBK Sorce Advisory LLC’s holdings in Capricor Therapeutics were worth $1,141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in CAPR. Farther Finance Advisors LLC bought a new position in Capricor Therapeutics during the 3rd quarter worth $28,000. Sheets Smith Investment Management acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth $107,000. First Financial Bank Trust Division bought a new position in shares of Capricor Therapeutics in the third quarter worth $203,000. Tower Research Capital LLC TRC increased its position in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Capricor Therapeutics by 2,342.8% in the second quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 34,908 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 22nd. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research note on Monday, December 15th. Finally, HC Wainwright lifted their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $30.04 on Tuesday. Capricor Therapeutics, Inc. has a one year low of $4.30 and a one year high of $40.37. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -16.69 and a beta of 0.62. The firm has a 50 day simple moving average of $14.25 and a 200 day simple moving average of $10.04.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). As a group, analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.